BR112022026615A2 - Produtos combinados em dose tripla fixa de antibióticos, regime de dosagem, métodos e kits para tratamento de infecções por micobactérias pulmonares não tuberculosas - Google Patents
Produtos combinados em dose tripla fixa de antibióticos, regime de dosagem, métodos e kits para tratamento de infecções por micobactérias pulmonares não tuberculosasInfo
- Publication number
- BR112022026615A2 BR112022026615A2 BR112022026615A BR112022026615A BR112022026615A2 BR 112022026615 A2 BR112022026615 A2 BR 112022026615A2 BR 112022026615 A BR112022026615 A BR 112022026615A BR 112022026615 A BR112022026615 A BR 112022026615A BR 112022026615 A2 BR112022026615 A2 BR 112022026615A2
- Authority
- BR
- Brazil
- Prior art keywords
- fixed dose
- mac
- treatment
- fixed
- tuberculous
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000002685 pulmonary effect Effects 0.000 title abstract 3
- 239000003242 anti bacterial agent Substances 0.000 title abstract 2
- 229940088710 antibiotic agent Drugs 0.000 title abstract 2
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 abstract 3
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 abstract 3
- 229960002626 clarithromycin Drugs 0.000 abstract 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 3
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 abstract 3
- 229960004287 clofazimine Drugs 0.000 abstract 3
- 229940000425 combination drug Drugs 0.000 abstract 3
- 229960000885 rifabutin Drugs 0.000 abstract 3
- 208000019693 Lung disease Diseases 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 208000032376 Lung infection Diseases 0.000 abstract 1
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000022155 mycobacterium avium complex disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046322P | 2020-06-30 | 2020-06-30 | |
| US202063046335P | 2020-06-30 | 2020-06-30 | |
| PCT/IB2021/000451 WO2022003421A2 (en) | 2020-06-30 | 2021-06-30 | Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026615A2 true BR112022026615A2 (pt) | 2023-01-24 |
Family
ID=79032054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026615A BR112022026615A2 (pt) | 2020-06-30 | 2021-06-30 | Produtos combinados em dose tripla fixa de antibióticos, regime de dosagem, métodos e kits para tratamento de infecções por micobactérias pulmonares não tuberculosas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11590154B2 (enExample) |
| EP (1) | EP4171546A4 (enExample) |
| JP (1) | JP2023533472A (enExample) |
| KR (1) | KR20230028502A (enExample) |
| CN (1) | CN115768420A (enExample) |
| AU (1) | AU2021298936A1 (enExample) |
| BR (1) | BR112022026615A2 (enExample) |
| CA (1) | CA3187031A1 (enExample) |
| IL (1) | IL299287A (enExample) |
| MX (1) | MX2023000165A (enExample) |
| WO (1) | WO2022003421A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025026423A1 (en) * | 2023-08-02 | 2025-02-06 | Shenzhen Pharmacin Co., Ltd. | Compositions, their use and manufacture for treatment of gastrointestinal conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0971735T1 (sl) | 1997-04-01 | 2008-08-31 | Borody Thomas J | Postopek in sestavina za zdravljenje bolezni vnetja debelega äśrevesa |
| CA2714043C (en) | 2008-02-08 | 2016-11-08 | Giaconda Limited | Methods and compositions for treating inflammatory bowel disease |
| TWI573590B (zh) * | 2011-09-20 | 2017-03-11 | 雷希爾生藥有限公司 | 治療自體免疫疾病之組成物及方法 |
| CA3000709A1 (en) | 2015-10-01 | 2017-04-06 | Memorial Sloan-Kettering Cancer Center | Inhibitors of menaquinone biosynthesis |
| WO2017194734A1 (en) | 2016-05-13 | 2017-11-16 | Technische Universität München | Means and methods for treating mycobacterial diseases |
-
2021
- 2021-06-30 CA CA3187031A patent/CA3187031A1/en active Pending
- 2021-06-30 JP JP2022580214A patent/JP2023533472A/ja active Pending
- 2021-06-30 AU AU2021298936A patent/AU2021298936A1/en active Pending
- 2021-06-30 MX MX2023000165A patent/MX2023000165A/es unknown
- 2021-06-30 US US17/364,124 patent/US11590154B2/en active Active
- 2021-06-30 IL IL299287A patent/IL299287A/en unknown
- 2021-06-30 BR BR112022026615A patent/BR112022026615A2/pt unknown
- 2021-06-30 EP EP21834321.8A patent/EP4171546A4/en not_active Withdrawn
- 2021-06-30 KR KR1020237002839A patent/KR20230028502A/ko active Pending
- 2021-06-30 WO PCT/IB2021/000451 patent/WO2022003421A2/en not_active Ceased
- 2021-06-30 CN CN202180044988.XA patent/CN115768420A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11590154B2 (en) | 2023-02-28 |
| EP4171546A2 (en) | 2023-05-03 |
| CN115768420A (zh) | 2023-03-07 |
| AU2021298936A1 (en) | 2023-01-19 |
| WO2022003421A3 (en) | 2022-03-17 |
| IL299287A (en) | 2023-02-01 |
| JP2023533472A (ja) | 2023-08-03 |
| US20210401865A1 (en) | 2021-12-30 |
| WO2022003421A2 (en) | 2022-01-06 |
| MX2023000165A (es) | 2023-02-22 |
| KR20230028502A (ko) | 2023-02-28 |
| CA3187031A1 (en) | 2022-01-06 |
| EP4171546A4 (en) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McCARTHY | Pyostomatitis vegetans: report of three cases | |
| Elborn et al. | Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection | |
| OA12845A (en) | Single dose azithromycin for treating respiratory infections. | |
| Weiss et al. | Acute nonspecific lung abscess: a controlled study comparing orally and parenterally administered penicillin G | |
| Yuan et al. | Randomized controlled clinical trial on the efficacy of fosfomycin trometamol for uncomplicated gonococcal urethritis in men | |
| HUP0002125A2 (hu) | Tökéletesített retard hatású mikróbaellenes szerek | |
| Miller et al. | Successful treatment of actinomycosis with stilbamidine | |
| AU777508B2 (en) | Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate | |
| Brodie et al. | Comparative study of cefuroxime axetil and amoxycillin in the treatment of acute sinusitis in general practice | |
| MX2023000165A (es) | Productos de combinacion de dosis fijas de tres antibioticos, regimen de dosificacion, metodos y kits para tratar infecciones micobacterianas pulmonares no tuberculosas. | |
| BR0107881A (pt) | Uso de fsh tratamento de infertilidade | |
| Schwartz et al. | The Management of Massive Tuberculous Pneumonia, A Therapeutic Review of Seventy-Five Cases | |
| Eastlake Jr et al. | Use of para-aminosalicylic acid in chronic pulmonary tuberculosis | |
| HUP0201629A2 (hu) | Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása | |
| FINLAND et al. | Antibiotic Susceptibility and Phage Types of Pathogenic Staphylococci: A Study of Two Hundred Ten Strains Isolated at Boston City Hospital in 1955 | |
| Blanshard | Sputum viscosity and postoperative pulmonary atelectasis | |
| Becker et al. | Evaluation of antibiotics in the control of pustular acne vulgaris | |
| Goldstein et al. | Erythromycin for anaerobic pleuropulmonary and soft-tissue infections | |
| ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| LEVINE | Inhalation therapy in chronic bronchial infections | |
| PT100284B (pt) | Anti-helmintico de benzimidazol para uso no fabrico de um medicamento para o tratamento de infeccao microsporideos | |
| RU2189234C2 (ru) | Способ лечения туберкулеза органов дыхания с выраженной экссудативной реакцией у детей | |
| Whitby et al. | Comparison of fleroxacin and amoxicillin in the treatment of uncomplicated urinary tract infections in women | |
| DUNNER et al. | Streptomycin para-aminosalicylate in the treatment of pulmonary tuberculosis | |
| RU2391977C2 (ru) | Способ лечения острых форм бактериальных вагинитов |